A case of pathological complete regression in combined modality treatment of resectable her2/ neu-positive gastric cancer

Q4 Medicine

Siberian journal of oncology Pub Date : 2024-03-23 DOI:10.21294/1814-4861-2024-23-1-170-177

A. Avgustinovich, S. Afanasyev, L. V. Spirina, E. V. Kaygorodova, R. V. Ermolenko, E. N. Samtsov, I. Frolova, O. Cheremisina

引用次数: 0

Abstract

Background. Overexpression of Her2neu occurs in 15–20% of patients with gastric cancer and correlates with an unfavorable prognosis. Case report. We report a case of pathological complete regression of resectable gastric cancer with Her2/neu overexpression. The patient received combined modality treatment including 8 cycles of neoadjuvant chemotherapy with mFLOT + trastuzumab followed by R0 resection. The addition of targeted therapy did not have a negative impact on the perioperative period. Histolohical examination of the surgical specimen revealed pathological complete response (Mandart TGR1). Currently, the patient has been followed-up for 27 months without signs of disease relapse. Conclusion. Total neoadjuvant chemotherapy with mFLОТ+ trastuzumab for operable gastric cancer with Her2/neu overexpression allows us to hope for improved long-term treatment outcomes.

查看原文本刊更多论文

可切除 her2/ neu 阳性胃癌联合模式治疗病理完全消退病例

背景。15%-20%的胃癌患者体内存在 Her2neu 的过表达，这与预后不良有关。病例报告。我们报告了一例 Her2/neu 过度表达的可切除胃癌病理完全消退病例。患者接受了联合模式治疗，包括 8 个周期的 mFLOT + 曲妥珠单抗新辅助化疗，随后进行了 R0 切除术。靶向治疗的加入并未对围手术期产生负面影响。手术标本的组织学检查显示病理完全反应（Mandart TGR1）。目前，该患者已经接受了 27 个月的随访，没有出现疾病复发的迹象。结论对于Her2/neu过表达的可手术胃癌，采用mFLОТ+曲妥珠单抗的全新药辅助化疗可望改善长期治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Siberian journal of oncology Medicine-Oncology

CiteScore

0.40

自引率

0.00%

发文量

117

审稿时长

8 weeks

期刊介绍： The main objectives of the journal are: -to promote the establishment of Russia’s leading worldwide positions in the field of experimental and clinical oncology- to create the international discussion platform intended to cover all aspects of basic and clinical cancer research, including carcinogenesis, molecular biology, epidemiology, cancer prevention, diagnosis and multimodality treatment (surgery, chemotherapy, radiation therapy, hormone therapy), anesthetic management, medical and social rehabilitation, palliative care as well as the improvement of life quality of cancer patients- to encourage promising young scientists to be actively involved in cancer research programs- to provide a platform for researches and doctors all over the world to promote, share, and discuss various new issues and developments in cancer related problems. (to create a communication platform for the expansion of cooperation between Russian and foreign professional associations).- to provide the information about the latest worldwide achievements in different fields of oncology The most important tasks of the journal are: -to encourage scientists to publish their research results- to offer a forum for active discussion on topics of major interest - to invite the most prominent Russian and foreign authors to share their latest research findings with cancer research community- to promote the exchange of research information, clinical experience, current trends and the recent developments in the field of oncology as well as to review interesting cases encountered by colleagues all over the world- to expand the editorial board and reviewers with the involvement of well-known Russian and foreign experts- to provide open access to full text articles- to include the journal into the international database- to increase the journal’s impact factor- to promote the journal to the International and Russian markets